These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21124075)

  • 21. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
    Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
    Front Immunol; 2019; 10():1848. PubMed ID: 31440242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
    Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C
    Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regression of glioma in rat models by intranasal application of parvovirus h-1.
    Kiprianova I; Thomas N; Ayache A; Fischer M; Leuchs B; Klein M; Rommelaere J; Schlehofer JR
    Clin Cancer Res; 2011 Aug; 17(16):5333-42. PubMed ID: 21715567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic implications of the enhanced short and long-term cytotoxicity of radiation treatment followed by oncolytic parvovirus H-1 infection in high-grade glioma cells.
    Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
    Bioeng Bugs; 2010; 1(6):429-33. PubMed ID: 21468212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncolytic H-1 Parvovirus Hijacks Galectin-1 to Enter Cancer Cells.
    Ferreira T; Kulkarni A; Bretscher C; Nazarov PV; Hossain JA; Ystaas LAR; Miletic H; Röth R; Niesler B; Marchini A
    Viruses; 2022 May; 14(5):. PubMed ID: 35632759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
    Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J
    Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TLR-9 contributes to the antiviral innate immune sensing of rodent parvoviruses MVMp and H-1PV by normal human immune cells.
    Raykov Z; Grekova SP; Hörlein R; Leuchs B; Giese T; Giese NA; Rommelaere J; Zawatzky R; Daeffler L
    PLoS One; 2013; 8(1):e55086. PubMed ID: 23383065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluorescence In Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-Treated Human Brain Tumors.
    Kiprianova I; Just A; Leuchs B; Rommelaere J; Angelova AL
    Methods Mol Biol; 2020; 2058():295-306. PubMed ID: 31486047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells.
    Lacroix J; Leuchs B; Li J; Hristov G; Deubzer HE; Kulozik AE; Rommelaere J; Schlehofer JR; Witt O
    Int J Cancer; 2010 Sep; 127(5):1230-9. PubMed ID: 20087864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical Testing of an Oncolytic Parvovirus: Standard Protoparvovirus H-1PV Efficiently Induces Osteosarcoma Cell Lysis In Vitro.
    Geiss C; Kis Z; Leuchs B; Frank-Stöhr M; Schlehofer JR; Rommelaere J; Dinsart C; Lacroix J
    Viruses; 2017 Oct; 9(10):. PubMed ID: 29039746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Roadmap for the Success of Oncolytic Parvovirus-Based Anticancer Therapies.
    Hartley A; Kavishwar G; Salvato I; Marchini A
    Annu Rev Virol; 2020 Sep; 7(1):537-557. PubMed ID: 32600158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV.
    Angelova AL; Aprahamian M; Grekova SP; Hajri A; Leuchs B; Giese NA; Dinsart C; Herrmann A; Balboni G; Rommelaere J; Raykov Z
    Clin Cancer Res; 2009 Jan; 15(2):511-9. PubMed ID: 19147756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry.
    Kulkarni A; Ferreira T; Bretscher C; Grewenig A; El-Andaloussi N; Bonifati S; Marttila T; Palissot V; Hossain JA; Azuaje F; Miletic H; Ystaas LAR; Golebiewska A; Niclou SP; Roeth R; Niesler B; Weiss A; Brino L; Marchini A
    Nat Commun; 2021 Jun; 12(1):3834. PubMed ID: 34158478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis.
    Ferreira T; Kulkarni A; Bretscher C; Richter K; Ehrlich M; Marchini A
    Viruses; 2020 Oct; 12(10):. PubMed ID: 33096814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1.
    Josupeit R; Bender S; Kern S; Leuchs B; Hielscher T; Herold-Mende C; Schlehofer JR; Dinsart C; Witt O; Rommelaere J; Lacroix J
    Viruses; 2016 May; 8(5):. PubMed ID: 27213425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis.
    Lacroix J; Schlund F; Leuchs B; Adolph K; Sturm D; Bender S; Hielscher T; Pfister SM; Witt O; Rommelaere J; Schlehofer JR; Witt H
    Int J Cancer; 2014 Feb; 134(3):703-16. PubMed ID: 23852775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Oncolytic parvoviruses. A new approaches for cancer therapy].
    Loktev VB; Ivan'kina TIu; Netesov SV; Chumakov PM
    Vestn Ross Akad Med Nauk; 2012; (2):42-7. PubMed ID: 22642177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of a helper and not regulatory human CD4+ T cell response by oncolytic H-1 parvovirus.
    Moralès O; Richard A; Martin N; Mrizak D; Sénéchal M; Miroux C; Pancré V; Rommelaere J; Caillet-Fauquet P; de Launoit Y; Delhem N
    PLoS One; 2012; 7(2):e32197. PubMed ID: 22359669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid.
    Allaume X; El-Andaloussi N; Leuchs B; Bonifati S; Kulkarni A; Marttila T; Kaufmann JK; Nettelbeck DM; Kleinschmidt J; Rommelaere J; Marchini A
    J Virol; 2012 Apr; 86(7):3452-65. PubMed ID: 22258256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients.
    Angelova AL; Geletneky K; Nüesch JP; Rommelaere J
    Front Bioeng Biotechnol; 2015; 3():55. PubMed ID: 25954743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.